Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04270760 · ClinicalTrials.gov registry record · Phase 2
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 281
- Enrollment target
NCT04270760 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 281 participants.
The verdict
NCT04270760, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 281 participants
- Enrollment target
Study Summary
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).
Interventions
- DRUG Placebo
- DRUG Olpasiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2022-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04270760
The ClinicalTrials.gov registry entry for NCT04270760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04270760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04270760 about?
NCT04270760 is a clinical study titled "Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study". Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).
What is the current status of trial NCT04270760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 281 participants. The study started on 2020-07-28. Estimated completion is 2022-11-08.
What interventions are being tested in trial NCT04270760?
The interventions under investigation include: Placebo (DRUG), Olpasiran (DRUG).
Who is sponsoring clinical trial NCT04270760?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.